Novartis’s Fevipiprant Hit By Phase III Asthma Failure

ZEAL Studies Miss Efficacy In Moderate Disease

 
• By Eleanor Malone
Failed launch
Novartis's fevipiprant fails to fly in moderate asthma

More from Respiratory

More from Therapeutic Category